/DXCM
DXCM Stock - DexCom, Inc.
Healthcare|Medical - DevicesNASDAQ
$66.06+0.23%
+$0.15 (+0.23%) • Dec 19
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.40
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.59
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+28.7%upside
Target: $85.02
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DXCM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$65.40 – $66.72
TARGET (TP)$85.00
STOP LOSS$60.78
RISK/REWARD1:3.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.51
52W High$93.25
52W Low$54.11
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.03B | $3.62B | $2.91B | $2.45B | $1.93B |
| Gross Profit | $2.44B | $2.29B | $1.88B | $1.68B | $1.28B |
| Gross Margin | 60.5% | 63.2% | 64.7% | 68.6% | 66.4% |
| Operating Income | $600.00M | $597.70M | $391.20M | $265.80M | $299.50M |
| Net Income | $576.20M | $541.50M | $341.20M | $216.90M | $493.60M |
| Net Margin | 14.3% | 14.9% | 11.7% | 8.9% | 25.6% |
| EPS | $1.46 | $1.44 | $0.88 | $0.56 | $1.31 |
Company Overview
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
1
6%
Buy / Outperform
12
67%
Hold / Neutral
5
28%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
13 Bullish5 Neutral/Bearish
Price Targets
$108
Average Target
↑ 63.0% Upside
Now
$68
Low
$108
Average
$165
High
Based on 20 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 2nd 2025 | Morgan Stanley | Upgrade | Overweight | $75 |
| November 25th 2025 | Evercore ISI | Initiation | In-line | $68 |
| October 21st 2025 | Stifel | Resumed | Buy | $85 |
| September 8th 2025 | Oppenheimer | Downgrade | Perform | - |
| August 21st 2025 | Argus | Initiation | Buy | $100 |
| June 16th 2025 | Truist | Initiation | Buy | $102 |
| May 30th 2025 | Goldman | Initiation | Buy | $104 |
| April 10th 2025 | Mizuho | Initiation | Outperform | $85 |
| February 3rd 2025 | Redburn Atlantic | Upgrade | Buy | $115← $85 |
| January 16th 2025 | Robert W. Baird | Upgrade | Outperform | $104← $86 |
| July 26th 2024 | Robert W. Baird | Downgrade | Neutral | $80← $161 |
| July 26th 2024 | JP Morgan | Downgrade | Neutral | $75← $145 |
| May 30th 2024 | Redburn Atlantic | Initiation | Neutral | $130 |
| March 12th 2024 | RBC Capital Mkts | Initiation | Outperform | $165 |
| May 30th 2023 | Morgan Stanley | Resumed | Equal Weight | $131 |
Earnings History & Surprises
DXCMBeat Rate
72%
Last 18 quarters
Avg Surprise
+14.3%
EPS vs Estimate
Beats / Misses
13/4
1 met exactly
Latest EPS
$0.61
Q4 2025
EPS Surprise History
Q1 24
+16.3%
$0.50vs$0.43
Q2 24
+18.5%
$0.32vs$0.27
Q3 24
+10.3%
$0.43vs$0.39
Q4 24
+2.3%
$0.45vs$0.44
Q1 25
-6.1%
$0.45vs$0.48
Q2 25
-2.2%
$0.32vs$0.33
Q3 25
+8.2%
$0.48vs$0.44
Q4 25
+5.9%
$0.61vs$0.58
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 12, 2026 | $0.65 | — | — | — |
Q4 2025 | Oct 30, 2025 | $0.58 | $0.61 | +5.9% | ✓ BEAT |
Q3 2025 | Jul 30, 2025 | $0.44 | $0.48 | +8.2% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $0.33 | $0.32 | -2.2% | ✗ MISS |
Q1 2025 | Feb 13, 2025 | $0.48 | $0.45 | -6.1% | ✗ MISS |
Q4 2024 | Oct 24, 2024 | $0.44 | $0.45 | +2.3% | ✓ BEAT |
Q3 2024 | Jul 25, 2024 | $0.39 | $0.43 | +10.3% | ✓ BEAT |
Q2 2024 | Apr 25, 2024 | $0.27 | $0.32 | +18.5% | ✓ BEAT |
Q1 2024 | Feb 8, 2024 | $0.43 | $0.50 | +16.3% | ✓ BEAT |
Q4 2023 | Oct 26, 2023 | $0.34 | $0.50 | +47.1% | ✓ BEAT |
Q3 2023 | Jul 27, 2023 | $0.23 | $0.34 | +47.8% | ✓ BEAT |
Q2 2023 | Apr 27, 2023 | $0.15 | $0.17 | +13.3% | ✓ BEAT |
Q1 2023 | Feb 9, 2023 | $0.26 | $0.34 | +30.8% | ✓ BEAT |
Q4 2022 | Oct 27, 2022 | $0.24 | $0.28 | +16.7% | ✓ BEAT |
Q3 2022 | Jul 28, 2022 | $0.17 | $0.17 | 0.0% | = MET |
Q2 2022 | Apr 28, 2022 | $0.13 | $0.08 | -38.5% | ✗ MISS |
Q1 2022 | Feb 10, 2022 | $0.22 | $0.17 | -22.7% | ✗ MISS |
Q4 2021 | Oct 28, 2021 | $0.16 | $0.22 | +37.5% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $0.11 | $0.19 | +72.7% | ✓ BEAT |
Latest News
Mizuho Maintains Outperform on DexCom, Raises Price Target to $78
📈 PositiveBenzinga•Dec 17, 2025, 12:57 PM
Citigroup Maintains Buy on DexCom, Raises Price Target to $77
📈 PositiveBenzinga•Dec 11, 2025, 08:58 PM•Also:
Morgan Stanley Upgrades DexCom to Overweight, Raises Price Target to $75
📈 PositiveBenzinga•Dec 2, 2025, 05:34 PM
Evercore ISI Group Initiates Coverage On DexCom with In-Line Rating, Announces Price Target of $68
➖ NeutralBenzinga•Nov 25, 2025, 12:54 PM
DexCom Receives FDA Clearance For Its Dexcom Smart Basal Insulin Dosing Optimizer For Patients With Type 2 Diabetes
📈 PositiveBenzinga•Nov 19, 2025, 01:36 PM
Morgan Stanley Maintains Equal-Weight on DexCom, Lowers Price Target to $63
➖ NeutralBenzinga•Nov 10, 2025, 05:48 PM
DexCom shares are trading lower after Argus Research cut its price target from $100 to $90.
📉 NegativeBenzinga•Nov 7, 2025, 06:56 PM
Argus Research Maintains Buy on DexCom, Lowers Price Target to $90
➖ NeutralBenzinga•Nov 7, 2025, 04:42 PM
Reported Earlier, Dexcom Applauds Québec Government For Expanding RAMQ Coverage Of Continuous Glucose Monitoring For Eligible Type 2 Diabetes Patients
📈 PositiveBenzinga•Nov 7, 2025, 08:11 AM
UBS Maintains Buy on DexCom, Lowers Price Target to $95
➖ NeutralBenzinga•Nov 3, 2025, 09:09 PM
Truist Securities Reiterates Buy on DexCom, Lowers Price Target to $82
📈 PositiveBenzinga•Nov 3, 2025, 03:13 PM
Barclays Maintains Equal-Weight on DexCom, Lowers Price Target to $80
➖ NeutralBenzinga•Nov 3, 2025, 02:34 PM•Also:
Wells Fargo Maintains Overweight on DexCom, Lowers Price Target to $93
➖ NeutralBenzinga•Oct 31, 2025, 09:18 PM
Canaccord Genuity Maintains Buy on DexCom, Lowers Price Target to $99
➖ NeutralBenzinga•Oct 31, 2025, 08:30 PM•Also:
Citigroup Maintains Buy on DexCom, Lowers Price Target to $75
➖ NeutralBenzinga•Oct 31, 2025, 07:44 PM•Also:
JP Morgan Maintains Neutral on DexCom, Lowers Price Target to $75
➖ NeutralBenzinga•Oct 31, 2025, 07:08 PM
TD Cowen Maintains Buy on DexCom, Lowers Price Target to $84
➖ NeutralBenzinga•Oct 31, 2025, 05:51 PM
DexCom slips after earnings on margin trends, 2026 growth concerns
📉 NegativeSeeking Alpha•Oct 31, 2025, 03:53 PM
Piper Sandler Maintains Overweight on DexCom, Lowers Price Target to $75
➖ NeutralBenzinga•Oct 31, 2025, 03:41 PM
RBC Capital Maintains Outperform on DexCom, Lowers Price Target to $85
➖ NeutralBenzinga•Oct 31, 2025, 02:49 PM
Frequently Asked Questions about DXCM
What is DXCM's current stock price?
DexCom, Inc. (DXCM) is currently trading at $66.06 per share. The stock has moved +0.23% today.
What is the analyst price target for DXCM?
The average analyst price target for DXCM is $85.00, based on 1 analyst.
What sector is DexCom, Inc. in?
DexCom, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is DXCM's market cap?
DexCom, Inc. has a market capitalization of $25.84 billion, making it a large-cap company.
Does DXCM pay dividends?
No, DexCom, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBIIB
Biogen Inc.
$174.80
Mkt Cap: $25.6B
LH
Labcorp Holdings Inc.
$252.03
Mkt Cap: $20.9B
PHG
Koninklijke Philips N.V.
$26.66
Mkt Cap: $25.4B
PODD
Insulet Corporation
$289.62
Mkt Cap: $20.4B
SNN
Smith & Nephew plc
$32.82
Mkt Cap: $14.4B
STE
STERIS plc
$254.34
Mkt Cap: $25.0B
TEVA
Teva Pharmaceutical Industries Limited
$30.35
Mkt Cap: $34.8B
WAT
Waters Corporation
$378.03
Mkt Cap: $22.5B
WST
West Pharmaceutical Services, Inc.
$272.54
Mkt Cap: $19.6B
ZBH
Zimmer Biomet Holdings, Inc.
$89.13
Mkt Cap: $17.7B
Explore stocks similar to DXCM for comparison